facebook pixel
Holding the Makers of Taxotere Responsible

When Was Taxotere Approved?

Taxotere, a potent chemotherapy drug, has played a role in treating various types of cancer since its approval. However, the controversies surrounding its side effects, particularly permanent hair loss, have raised questions about the drug’s safety and the responsibility of pharmaceutical companies to provide adequate warnings to patients.

If you have suffered severe side effects after receiving Taxotere treatments, contact the experienced Taxotere injury lawsuit attorneys at Hotze Runkle PLLC to learn more about your legal options. Call us at (800) 763-6155 for a free consultation or take our online quiz to see whether you qualify for compensation.

Taxotere’s Introduction and Approval in France

The story of Taxotere’s approval began in France. Rhône-Poulenc Rorer, a French pharmaceutical company, developed the drug in the 1980s. The compound, also known as docetaxel, showed promising results as a chemotherapy agent in preclinical studies. In 1994, France became the first country to approve Taxotere to treat advanced breast cancer.

Approval in the United States

Following its approval in France, Taxotere caught the attention of the United States Food and Drug Administration (FDA). The FDA reviews and approves drugs for use in the United States after thoroughly evaluating their safety and efficacy. In May 1996, the FDA granted approval for Taxotere to treat advanced breast cancer in patients who had not responded to previous chemotherapy treatments. This approval marked a significant milestone in the drug’s journey. After that, it became widely accessible to patients in the United States.

Expanded Approval in the United States

Since its initial approval, the FDA has expanded the approved indications for Taxotere use in the United States. These additional approvals include the following:

  • In 1999, Taxotere received approval for use in combination with the drug cisplatin to treat advanced non-small cell lung cancer (NSCLC).
  • In 2004, the FDA approved Taxotere for treating metastatic prostate cancer, specifically in combination with prednisone.
  • In 2006, Taxotere gained approval for use in combination with doxorubicin and cyclophosphamide to treat early-stage breast cancer after surgery.
  • In 2007, the FDA approved Taxotere for use in combination with fluorouracil and cisplatin to treat advanced gastric cancer, including cancer of the gastroesophageal junction.
  • In 2010, Taxotere received approval for use in combination with cisplatin and fluorouracil to treat inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN).

These expanded indications mean that many cancer patients have used Taxotere as a treatment option for their specific types of cancer.

Global Approval of Taxotere

Over time, Taxotere has gained approval in numerous countries worldwide, including the United Kingdom, Canada, Australia, and many European and Asian nations. The drug’s global approval has made it a chemotherapy option for millions of patients with different types of cancer.

Taxotere’s Impact on Cancer Treatment

Since its approval, Taxotere has become one of the most widely prescribed chemotherapy drugs. Healthcare professionals commonly administer Taxotere as a part of combination chemotherapy regimens, often in conjunction with other chemotherapy drugs, in attempts to maximize its efficacy in targeting and destroying cancer cells.

Taxotere’s and Permanent Hair Loss

While Taxotere has been effective in treating cancer, it has faced controversies due to its side effects, particularly permanent hair loss (alopecia). Temporary hair loss is a common side effect of many chemotherapy drugs, but the makers of Taxotere did not initially disclose the risk of permanent hair loss. This omission has led to numerous personal injury lawsuits against Sanofi-Aventis, the pharmaceutical company marketing Taxotere in the United States.

Legal Implications of Taxotere-Related Alopecia

Patients who have experienced permanent hair loss after using Taxotere may be eligible to file personal injury lawsuits against Sanofi-Aventis. These lawsuits allege that the company failed to warn patients and healthcare professionals about the risk of permanent hair loss. Successful personal injury claims can result in financial compensation for medical expenses, emotional distress, and other damages related to the side effects of Taxotere.

Taxotere’s Connection to Canalicular Stenosis

Besides the controversial side effect of permanent hair loss, Taxotere has also been linked to a rare but serious eye condition known as canalicular stenosis. Canalicular stenosis is a condition where the tear ducts (canaliculi) narrow and become obstructed, leading to excessive tearing, eye pain, and potential vision loss.

Recent studies have found a correlation between the use of Taxotere and the development of canalicular stenosis. The drug’s secretions can cause inflammation and fibrosis of the tear ducts, ultimately leading to their narrowing and blockage. Patients suffering from this condition may require surgical intervention, such as dacryocystorhinostomy (DCR), to restore tear drainage and prevent further complications.

Legal Implications of Canalicular Stenosis

Patients who have developed canalicular stenosis after undergoing Taxotere chemotherapy treatment may be eligible to file personal injury lawsuits against Sanofi-Aventis. The grounds of these lawsuits are that the pharmaceutical company failed to adequately warn the public about the risk of canalicular stenosis and the potential need for surgical intervention.

Victims of Taxotere-related canalicular stenosis may be entitled to compensation for medical expenses, including the cost of surgery, as well as for emotional distress and other damages related to this eye condition. It is essential for patients experiencing symptoms of canalicular stenosis to consult with a personal injury attorney experienced in handling Taxotere cases.

Consult an Experienced Taxotere Injury Attorney

If you or a loved one has developed canalicular stenosis, permanent hair loss, or other severe side effects after receiving Taxotere chemotherapy, contact a qualified attorney as soon as possible. An experienced Taxotere personal injury lawyer can evaluate your case, help you understand your legal rights, and guide you through your legal pursuit of compensation for your losses.

The skilled and knowledgeable attorneys at Hotze Runkle PLLC have thoroughly researched the adverse side effects of Taxotere, and we understand the pain and distress this drug can cause. Our firm has recovered $100 million in compensation for our clients, and we are ready to put our experience to work for you. Call us today at (800) 763-6155 for a free consultation to learn more about how we can help you. Alternatively, take our online quiz to see if you might qualify for compensation.


Take the Quiz Now

Take our Quiz

Why Choose Hotze Runkle PLLC?

Hotze Runkle PLLC is a national litigation firm based in Texas who is experienced in handling defective drug cases. We personally have researched Taxotere and its unintended effects on its users. We are looking to help the victims of this very dangerous condition and spread awareness to prevent further damage.